Equities
Health CareMedical Equipment and Services
  • Price (SEK)47.72
  • Today's Change0.76 / 1.62%
  • Shares traded84.48k
  • 1 Year change-16.63%
  • Beta1.8386
Data delayed at least 15 minutes, as of Apr 23 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.

  • Revenue in SEK (TTM)2.25bn
  • Net income in SEK-1.70bn
  • Incorporated2016
  • Employees884.00
  • Location
    BICO Group ABLangfilsgatan 9GOETEBORG 412 77SwedenSWE
  • Phone+46 3 112874646
  • Websitehttps://bico.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Pulsion Medical Systems SE367.38m62.71m1.67bn66.0026.725.2121.224.560.65490.65493.843.360.97111.773.88479,840.0016.5820.3721.2431.1763.6655.9617.0724.121.7715.740.001,227.726.103.02-8.06----0.00
Amplitude Surgical SA1.21bn501.46m1.70bn416.003.401.552.681.410.90020.90022.171.970.39550.56528.83244,244.1016.21-0.365819.44-0.426779.4178.3040.98-1.081.210.41630.5395--14.44-0.0271993.58--7.11--
Prim SA2.51bn147.01m1.98bn900.0013.421.357.500.78690.7450.74512.737.401.121.994.10240,567.406.586.689.248.9037.9338.115.856.431.22--0.1681--9.7710.0051.02-2.1412.86--
Onward Medical NV0.00-418.31m2.02bn96.00--4.42-----1.19-1.190.001.140.00----0.00-47.61---52.97-------------32.110.3163------4.49------
Bactiguard Holding AB223.17m-138.38m2.11bn217.00--6.75--9.46-3.95-3.956.3710.080.30374.376.931,028,447.00-18.83-7.56-24.62-8.8127.4747.91-62.01-26.280.6445-8.670.3976---11.966.46-161.71--8.43--
Detection Technology Oyj-1.16tn-1.16tn2.29bn478.00--2.71----------4.97----------9.34--11.96--47.44--8.223.13--0.08153.455.292.027.55-18.03-14.88-9.55
Semperit Holding AG8.36bn291.52m2.82bn4.58k9.610.57083.890.33671.23-0.816235.1720.670.80984.688.24157,578.902.795.253.607.3222.4624.793.455.591.384.920.342686.85-7.54-3.87-34.59---7.21--
Tristel Plc530.97m81.17m2.84bn213.0035.426.7824.725.360.12560.12560.82190.65670.9921.516.26185,394.4015.178.8617.1010.2482.5980.6315.2910.633.93411.730.1605109.9915.7010.14351.986.409.8818.05
Medistim ASA521.52m102.87m3.20bn152.0031.018.0925.326.135.685.6828.7721.771.070.86465.983,462,921.0021.0122.9326.1428.5278.6778.2519.7220.642.61--0.042575.257.0010.06-8.9112.720.03314.87
BICO Group AB2.25bn-1.70bn3.24bn884.00--0.6788--1.44-23.61-27.6631.6069.180.24872.243.062,545,136.00-18.77---20.89--52.34---75.47--1.91-1.050.2852--6.09---1,889.33------
Nyxoah SA50.44m-501.30m3.34bn147.00--2.94--66.25-1.55-1.550.15553.420.03220.78912.0629,618.53-31.98-23.73-35.88-25.9861.9162.42-993.86-1,469.594.50--0.1147--40.99---38.39--100.58--
Lumibird SA2.36bn82.67m3.65bn1.05k39.341.6212.851.550.35590.35599.148.620.52381.094.05193,497.101.833.132.443.9961.6861.763.505.891.622.470.42870.006.6015.12-37.23-2.4718.34--
COLTENE Holding AG2.90bn142.63m3.78bn1.20k26.483.2716.851.302.002.0040.6216.211.331.406.58201,937.606.5310.4810.9018.7464.2462.684.927.470.80455.620.317279.94-9.133.54-54.05-6.81-7.72-7.79
IVF Hartmann Holding AG1.77bn180.85m4.10bn304.0022.662.2716.602.326.316.3161.6363.070.80153.088.46486,687.508.217.299.998.9053.9053.2910.248.303.89--0.005652.16-1.792.0934.951.49-14.8326.82
Ion Beam Applications SA4.97bn-105.68m4.63bn1.85k--3.61165.540.931-0.313-0.31314.733.650.7022.542.73---1.491.55-5.924.3231.3635.23-2.122.380.71030.94170.281443.0618.6710.74-250.40---8.06--
Data as of Apr 23 2024. Currency figures normalised to BICO Group AB's reporting currency: Swedish Krona SEK

Institutional shareholders

24.86%Per cent of shares held by top holders
HolderShares% Held
Handelsbanken Fonder ABas of 31 Mar 20246.93m10.03%
Fj�rde AP-fondenas of 25 Mar 20244.44m6.42%
Tredje AP-fondenas of 31 Jan 20242.38m3.44%
Deka Investment GmbHas of 31 Jan 20241.15m1.67%
ARK Investment Management LLCas of 05 Apr 20241.08m1.56%
SEB Investment Management ABas of 28 Mar 2024440.98k0.64%
Storebrand Asset Management ASas of 31 Jan 2024337.08k0.49%
Carnegie Investment Bank AB (Investment Management Denmark)as of 31 Dec 2021162.88k0.24%
E. �hman J :or Fonder ABas of 31 Mar 2024134.22k0.19%
SSgA Funds Management, Inc.as of 04 Apr 2024130.78k0.19%
More ▼
Data from 31 Dec 2021 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.